Go Pro
OTCMKTS:KNBWY

Kirin Q1 2026 Earnings Report

Kirin logo
$18.86 -0.04 (-0.23%)
As of 01:01 PM Eastern

Kirin EPS Results

Actual EPS
$0.21
Consensus EPS
$0.26
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Kirin Revenue Results

Actual Revenue
$3.62 billion
Expected Revenue
$3.63 billion
Beat/Miss
Missed by -$10.56 million
YoY Revenue Growth
N/A

Kirin Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Kirin Earnings Headlines

Kirin (OTCMKTS:KNBWY) Hits New 52-Week High on Earnings Beat
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.tc pixel
Kirin Holdings Co Ltd ADR KNBWY
See More Kirin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kirin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kirin and other key companies, straight to your email.

About Kirin

Kirin (OTCMKTS:KNBWY) Holdings Company, Limited is a Japan-based global beverage and life sciences group best known for its flagship beer brand. The company’s core operations encompass the brewing and distribution of beer and spirits, the production of soft drinks and other non-alcoholic beverages, and a growing pharmaceuticals and biotech segment. Kirin’s beverage portfolio ranges from mainstream lagers and craft-inspired brews to juices, teas, and carbonated soft drinks sold under various regional labels.

Rooted in the founding of Kirin Brewery Company in 1888, the group restructured into a pure holding company in 2007 to foster greater strategic flexibility. Over more than a century of expansion, Kirin has grown beyond Japan to establish a presence across Asia, Oceania, the Americas and Europe. Notable milestones include its majority stake in Australia’s Lion Nathan, partnerships with Chinese soft-drink bottlers, and the 2019 consolidation of its global pharmaceutical operations under Kyowa Kirin Co., Ltd., focusing on oncology, immunology and nephrology therapies.

The company is led by President and CEO Yoshinori Isozaki, who took the helm in April 2021. Under his stewardship, Kirin has emphasized sustainable practices—from water stewardship at its breweries to circular packaging initiatives—and continues to explore growth opportunities in health science through R&D investments. With a diversified business model spanning beverages and life sciences, Kirin Holdings leverages its century-long heritage to pursue innovation and resilience in global markets.

View Kirin Profile